HNSCC Clinical Trials

74 recruitingLast updated: June 17, 2026

There are 74 actively recruiting hnscc clinical trials across 30 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1. Top locations include Boston, Massachusetts, United States, Nashville, Tennessee, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


HNSCC Trials at a Glance

74 actively recruiting trials for hnscc are listed on ClinicalTrialsFinder across 6 cities in 30 countries. The largest study group is Phase 1 with 38 trials, with the heaviest enrollment activity in Boston, Nashville, and New York. Lead sponsors running hnscc studies include West China Hospital, Dan Zandberg, and Sun Yat-sen University.

Browse hnscc trials by phase

Treatments under study

About HNSCC Clinical Trials

Looking for clinical trials for HNSCC? There are currently 37 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HNSCC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HNSCC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 74 trials

Recruiting
Phase 1

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

SarcomaNon-small Cell Lung CancerNSCLC+12 more
Epkin146 enrolled10 locationsNCT06789172
Recruiting
Phase 1

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198
Recruiting
Phase 1

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Head and NeckHead and Neck Squamous Cell Carcinoma (HNSCC)Head and Neck Cancer+12 more
EpiBiologics110 enrolled6 locationsNCT07462377
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+9 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Phase 1Phase 2

EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC

Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaBiomarker-positive EGFR/HER2- Expressing HNSCC
Beijing Biotech42 enrolled1 locationNCT07617805
Recruiting
Phase 1Phase 2

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 3

Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Groupe Oncologie Radiotherapie Tete et Cou780 enrolled1 locationNCT07264075
Recruiting
Phase 2

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)Neoadjuvant TherapyHead and Neck Squamous Cell Carcinoma+1 more
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine182 enrolled1 locationNCT07601737
Recruiting
Phase 3

Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas.

HNSCC
Oslo University Hospital400 enrolled4 locationsNCT07580300
Recruiting
Phase 2

Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors

Margin AssessmentSquamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Medical University of South Carolina30 enrolled1 locationNCT07149207
Recruiting
Phase 1

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Head and Neck CancerHNSCCColo-rectal Cancer+4 more
ALX Oncology Inc.170 enrolled8 locationsNCT07085091
Recruiting
Phase 1

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

NeuroblastomaNasopharyngeal CarcinomaRhabdomyosarcoma+7 more
Sun Yat-sen University51 enrolled1 locationNCT07584499
Recruiting
Early Phase 1

Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer

HNSCCSCC - Squamous Cell CarcinomaHNSCC,Larynx, Pharynx and Oral Cavity
Vanderbilt-Ingram Cancer Center18 enrolled1 locationNCT06819228
Recruiting
Not Applicable

High-Resolution PET-CT Imaging for Surgical Margin Visualization

CancerHNSCCSCC - Squamous Cell Carcinoma+2 more
Vanderbilt-Ingram Cancer Center50 enrolled1 locationNCT06915454
Recruiting
Phase 2

[68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas

Head and Neck Squamous Cell Carcinoma (HNSCC)
John O. Prior20 enrolled1 locationNCT06794372
Recruiting
Phase 2

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)
Regeneron Pharmaceuticals120 enrolled10 locationsNCT06769698
Recruiting
Phase 2Phase 3

Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies

Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
All India Institute of Medical Sciences369 enrolled1 locationNCT07573956
Recruiting
Phase 1

Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

HNSCC
Beijing Tongren Hospital10 enrolled1 locationNCT07040072